
Symbiotec Pharmalab IPO
- Issue price
- ₹988
- Listing price
- ₹988
- 0.00%
- Current price
- ₹1,611.3
- +63.09%
- Subscribed
- 71.26x
- Issue size
- ₹1,757 Cr
- Listed on
- 1 Sep 2026
IPO timeline
- Opens24 AugMon
- Closes27 AugThu
- Allotment28 AugFri
- Refunds31 AugMon
- Demat credit31 AugMon
- Listing1 SepTue
Issue details
- Price band
- ₹938 – ₹988 per share
- Issue size
- ₹1,757 Cr
- Fresh issue
- Not available
- Offer for sale
- Not available
- Issue type
- Fresh capital cum OFS
- Face value
- ₹2 per share
- Lot size
- 15 shares
- Minimum investment
- ₹14,820
- Listing on
- BSE, NSE
- Exchange code
- SYMBIOTEC · 7907
This issue combines a fresh issue and an offer for sale. The amounts for each part are not available in our data; see the offer document for the split.
Lot size and investment
| Application | Lots | Shares | Amount |
|---|---|---|---|
| Retail (Min) | 1 | 15 | ₹14,820 |
| Retail (Max) | 13 | 195 | ₹1,92,660 |
| S-HNI (Min) | 14 | 210 | ₹2,07,480 |
| B-HNI (Min) | 68 | 1,020 | ₹10,07,760 |
Reservation
- QIB
- Not more than 50% of the Net Offer
- Retail
- Not less than 35.00% of the Net Offer
- NII
- Not less than 15% of the Net Offer
Allotment status
The allotment for this IPO is final. Check whether you received shares on the registrar's website using your PAN, application number or demat account (DP / Client ID).
Check allotment on MUFG Intime India- 1Open the registrar's allotment page and select this IPO from the list.
- 2Enter your PAN, application number or DP / Client ID.
- 3Submit to see the number of shares allotted, if any.
- Basis of allotment
- 28 Aug 2026
- Refunds initiated
- 31 Aug 2026
- Shares credited to demat
- 31 Aug 2026
- Listing
- 1 Sep 2026
Grey market premium (GMP)
- Current GMP
- ₹185
- +18.72%
- Estimated listing price
- ₹1,173
- Issue price ₹988
- Highest
- ₹410
- 22 Aug
- Lowest
- ₹185
- 31 Aug
GMP by day (₹ per share)
Day-wise GMP table
| Date | GMP | Premium | Est. listing |
|---|---|---|---|
| 1 Sep 2026 | ₹185 | +18.72% | ₹1,173 |
| 31 Aug 2026 | ₹185 | +18.72% | ₹1,173 |
| 30 Aug 2026 | ₹240 | +24.29% | ₹1,228 |
| 29 Aug 2026 | ₹240 | +24.29% | ₹1,228 |
| 28 Aug 2026 | ₹265 | +26.82% | ₹1,253 |
| 27 Aug 2026 | ₹270 | +27.33% | ₹1,258 |
| 26 Aug 2026 | ₹295 | +29.86% | ₹1,283 |
| 25 Aug 2026 | ₹352 | +35.63% | ₹1,340 |
| 24 Aug 2026 | ₹335 | +33.91% | ₹1,323 |
| 23 Aug 2026 | ₹409 | +41.40% | ₹1,397 |
| 22 Aug 2026 | ₹410 | +41.50% | ₹1,398 |
| 21 Aug 2026 | ₹345 | +34.92% | ₹1,333 |
| 20 Aug 2026 | ₹300 | +30.36% | ₹1,288 |
| 19 Aug 2026 | ₹220 | +22.27% | ₹1,208 |
GMP is an unofficial indicator from an unregulated market. It is shown for information only and is not a prediction of the listing price or a recommendation to apply.
Subscription status
- QIB172.03x
- NII (HNI)73.63x
- Retail12.96x
- Employee15.41x
| Category | Shares offered | Shares bid for | Subscribed |
|---|---|---|---|
| Qualified Institutional Buyers (QIB) | 37,39,872 | 64,33,59,195 | 172.03x |
| Non-Institutional Investors (NII) | 28,04,904 | 20,65,35,120 | 73.63x |
| bNII — bids above ₹10 Lakh | 18,69,936 | 15,50,46,495 | 82.92x |
| sNII — bids ₹2 Lakh to ₹10 Lakh | 9,34,968 | 5,14,88,625 | 55.07x |
| Retail Individual Investors (RII) | 65,44,776 | 8,48,10,330 | 12.96x |
| Employee | 35,377 | 5,45,055 | 15.41x |
| Total | 1,31,24,929 | 93,52,49,700 | 71.26x |
Financials
- P/E Ratio
- 56.81
- EPS (₹)
- 17.39
- RoE
- 11.19%
- RoCE
- 11.56%
- RoNW
- 9.48%
- PAT Margin
- 12.60%
- EBITDA Margin
- 26.59%
- NAV (₹)
- 184.69
Separate pre- and post-issue P/E are not available for this IPO; the P/E shown is as disclosed for the issue.
| Period ended | 31 Mar 2026 | 31 Mar 2025 | 31 Mar 2024 |
|---|---|---|---|
| Assets | 1,780.79 | 1,579.65 | 1,294.79 |
| Total Income | 872.26 | 755.98 | 723.33 |
| Profit After Tax | 109.90 | 96.79 | 100.06 |
| EBITDA | 231.97 | 206.11 | 177.04 |
| NET Worth | 1,158.64 | 821.15 | 720.68 |
| Reserves and Surplus | 1,145.95 | 810.03 | 709.54 |
| Total Borrowing | 387.91 | 540.92 | 247.21 |
Peer comparison
| Company | Issue size | P/E | RoNW | PAT margin | Subscribed | Listing gain |
|---|---|---|---|---|---|---|
| Symbiotec Pharmalab This IPO | ₹1,757 Cr | 56.81 | 9.48% | 12.60% | 71.26x | 0.00% |
| Indegene Mainboard · listed 13 May 2024 | ₹1,841.76 Cr | 33.53 | 18.23% | 12.62% | 70.3x | +44.91% |
| Akums Drugs & Pharmaceuticals Mainboard · listed 6 Aug 2024 | ₹1,856.74 Cr | 13580 | -0.57% | 0.02% | 63.44x | +6.77% |
| Entero Healthcare Solutions Mainboard · listed 16 Feb 2024 | ₹1,600 Cr | 129.75 | -1.86% | 4.69% | 1.56x | -2.33% |
| Sagility India Mainboard · listed 12 Nov 2024 | ₹2,106.4 Cr | 61.52 | 0.29% | 11.83% | 3.2x | +3.53% |
| Paras Healthcare Mainboard · listed 28 Oct 2026 | ₹1,450 Cr | 37.72 | 11.83% | 10.38% | 2.23x | +3.90% |
| Rubicon Research Mainboard · listed 16 Oct 2025 | ₹1,378 Cr | 46.13 | 29.02% | 10.37% | 109.32x | +27.84% |
Peers are other recent IPOs from the same industry, closest in issue size. Ratios are as disclosed at the time of each issue. This is not the listed-peer table from the offer document.
IPO objectives
How Symbiotec Pharmalab plans to use the money raised, as stated in the offer document.
- Prepayment and/or repayment, in full or in part, of all or a portion of certain outstanding borrowings availed by the Company₹112.5 Cr
- General corporate purposes
About Symbiotec Pharmalab
Symbiotec Pharmalab Ltd was set up in 2002. It is a pharmaceutical and biotechnology company that develops and makes active pharmaceutical ingredients, known as APIs, along with nutritional ingredients and specialty products. APIs are the actual medicine content that goes into a tablet or injection, which other pharma companies then turn into finished medicines. The company started in 1995 as a small lab scale maker of steroidal hormone APIs and has grown into a large backward integrated manufacturer with more than 30 years of experience in the field. It is a global leader in corticosteroid and steroidal hormone APIs. Its plants are approved by the United States Food and Drug Administration, by European Union Good Manufacturing Practices and by the Ministry of Food and Drug Safety of Korea, among other regulators. As on 30 June 2025 it ran two industrial scale API plants with a chemical synthesis capacity of 584.67 metric tonnes and a fermentation capacity of 300 kilolitres. It sells both in India and abroad, in regulated as well as emerging markets.
Strengths
- The company is a global leader in corticosteroid and steroidal hormone APIs, which is a specialised area with few makers worldwide.
- Its plants carry approvals from the US FDA, EU-GMP and the Korean drug regulator, which are hard to get and act as an entry barrier.
- Sales have grown every year, from Rs 723.33 crore in FY2024 to Rs 755.98 crore in FY2025 and Rs 872.26 crore in FY2026.
- EBITDA has improved steadily, from Rs 177.04 crore in FY2024 to Rs 206.11 crore in FY2025 and Rs 231.97 crore in FY2026.
- Borrowing was reduced sharply in the last year, from Rs 540.92 crore to Rs 387.91 crore, while net worth rose from Rs 821.15 crore to Rs 1,158.64 crore.
- The company is backward integrated and runs at industrial scale, with chemical synthesis capacity of 584.67 metric tonnes and fermentation capacity of 300 kilolitres.
- It has more than 30 years of experience in this line, having started as a lab scale steroid API maker in 1995.
- It sells into both regulated markets such as the USA and Europe and into emerging markets, so demand is not tied to one region.
Risks
- This is by far the most expensive issue in the current batch on earnings. At the upper band of Rs 988 the P/E is about 56.81 times on an EPS of Rs 17.39.
- Return ratios are low for that valuation. RoCE was 11.80% and RoNW was 11.79%.
- Profit has been almost flat for three years, at Rs 100.06 crore in FY2024, Rs 96.79 crore in FY2025 and Rs 109.90 crore in FY2026, even though assets grew from Rs 1,294.79 crore to Rs 1,780.79 crore over the same period.
- Very little of the issue money reaches the company. The stated objects account for only Rs 112.50 crore of borrowing repayment plus general corporate purposes, against a total issue of Rs 1,757 crore, which indicates that most of the issue is an offer for sale by existing shareholders.
- The pre issue and post issue promoter holding is not stated in the available data, so the extent of promoter dilution is not clear.
- API making is a regulated business. A negative inspection by the US FDA or the EU authorities at either plant can stop supply to those markets.
- The company is concentrated in steroid and corticosteroid APIs. A price fall or new capacity in that narrow segment would hit it directly.
- Borrowing is still sizeable at Rs 387.91 crore, and it had risen to Rs 540.92 crore in FY2025 before coming down, so the debt level has moved around a lot.
Promoters and shareholding
Anil Satwani, Kashish Satwani, Sushil Satwani and Satwani Holdings LLP
Anchor investors
Registrar, lead managers and documents
Company contact
385/2, Pigdamber, Rau, Mhow, Indore, Madhya Pradesh, 453331
+91 731 667 6405
secretarial@symbiotec.comSymbiotec Pharmalab IPO: common questions
1.When does the Symbiotec Pharmalab IPO open and close?
The Symbiotec Pharmalab IPO opens on 24 Aug 2026 and closes on 27 Aug 2026.
2.What is the price band of the Symbiotec Pharmalab IPO?
The price band is ₹938 – ₹988 per share, with a lot size of 15 shares and a minimum investment of ₹14,820.
3.What is the size of the Symbiotec Pharmalab IPO?
The issue size is ₹1,757 Cr (Fresh capital cum OFS).
4.What is the GMP of the Symbiotec Pharmalab IPO?
The last reported grey market premium is ₹185 per share as of 01 Sep 2026, 08:24 AM IST. GMP is unofficial and changes frequently.
5.When is the Symbiotec Pharmalab IPO allotment?
The basis of allotment is expected on 28 Aug 2026. Allotment status can be checked with the registrar, MUFG Intime India Private Limited.
6.When will the Symbiotec Pharmalab IPO list?
The shares listed on 1 Sep 2026 on BSE, NSE.
7.Who is the lead manager of the Symbiotec Pharmalab IPO?
The book running lead managers are JM Financial Ltd., Motilal Oswal Investment Advisors, Avendus Capital, and the registrar is MUFG Intime India Private Limited.
8.What will the money raised in the Symbiotec Pharmalab IPO be used for?
As stated in the offer document, the proceeds are for: Prepayment and/or repayment, in full or in part, of all or a portion of certain outstanding borrowings availed by the Company; General corporate purposes.
9.How can my company launch an IPO like Symbiotec Pharmalab?
Start with an IPO readiness assessment: eligibility for the Main Board, audited financials, governance, conversion to a public limited company and an indicative valuation. Be IPO Ready advises promoters through each step, from readiness to listing day.
For business owners
Your company could be the next listing
Businesses like these raise growth capital on the public markets every week. Tell us about yours and our advisors will tell you, plainly, whether an IPO is within reach and what it would take.
- Eligibility check against NSE Emerge, BSE SME and Main Board norms
- Indicative valuation and issue size for your business
- A clear timeline from readiness to listing day
Check if your business can list
Fill in the eligibility form and get an assessment of where you stand. It takes about five minutes.
Prefer to talk? Call +91 92130 20393